Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients.

Cell - 12 Nov 2020

Kim Dongsung, Xue Jenny Yaohua, Lito Piro

Abstract excerpt

KRAS mutations are among the most common genetic alterations in lung, colorectal, and pancreatic cancers. Direct inhibition of KRAS oncoproteins has been a long-standing pursuit in precision oncology, one established shortly after the discovery of RAS mutations in human cancer cells nearly 40 years ago. Recent advances in medicinal chemistry have established inhibitors targeting KRAS(G12C), a mutation found in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Clinical Trials as Topic
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melanoma and MAPK Pathways

Share to Molecular Targeted Therapy

Share to Mutation

Share to Protein Kinase Regulation and GTPase Signaling

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 33065029
DOI: 10.1016/j.cell.2020.09.044
PMCID: PMC7669705

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients.PMID 33065029Read ↗

Targeting KRAS in cancer.Semantic proximity Read ↗

Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges.Semantic proximity Read ↗

"Undruggable KRAS": druggable after all.Semantic proximity Read ↗

Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges.Semantic proximity Read ↗

Strategies for Targeting KRAS: A Challenging Drug Target.Semantic proximity Read ↗

Drugging KRAS: current perspectives and state-of-art review.Semantic proximity Read ↗

Targeting KRAS G12C in non-small cell lung cancer: Breakthrough inhibitors and combination approaches.Semantic proximity Read ↗

On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma.Semantic proximity Read ↗

Novel approaches for the development of direct KRAS inhibitors: structural insights and drug design.Semantic proximity Read ↗

Multiple medicinal chemistry strategies of targeting KRAS: State-of-the art and future directions.Semantic proximity Read ↗

From bench to bedside: current development and emerging trend of KRAS-targeted therapy.Semantic proximity Read ↗

The path to the clinic: a comprehensive review on direct KRASG12C inhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.